A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

计划入组 284 人 · 首次发布于 2019 年 7 月 30 日

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

计划入组 220 人 · 首次发布于 2023 年 8 月 1 日

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

计划入组 285 人 · 首次发布于 2023 年 8 月 3 日

Zipalertinib

CLN-619

CLN-049

RECIDA THERAPEUTICS, INC.

United States

Universidad Autónoma de Ciudad Juárez

Mexico

Dextech Medical AB

Sweden

Cullinan Oncology and Taiho Pharmaceutical Forge $275M Strategic Collaboration for EGFR Inhibitor CLN-081/TAS6417

Zipalertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion Mutations

Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 REZILIENT3 Trial for First-Line EGFR Exon 20 Insertion NSCLC